Columbia Endocrinology — Heidi Guzman, MD
180 Fort Washington Ave Ste 904 · New York, NY 10032
Retatrutide isn't available here yet. These are practices that treat weight and metabolic health, and some prescribe FDA-approved GLP-1s today. Inclusion does not mean a provider offers retatrutide.
180 Fort Washington Ave Ste 904 · New York, NY 10032
180 FORT WASHINGTON AVE · New York, NY 10032
1606 Saint Nicholas Avenue · New York, NY 10040
1230 YORK AVE · New York, NY 10021
462 1ST AVE · New York, NY 10016
423 E 23RD ST · New York, NY 10010
1165 YORK AVE, WEILL CORNELL MEDICAL COLLEGE · New York, NY 10065
111 BROADWAY FL 2 · New York, NY 10006
646 Park Avenue · New York, NY 10065
550 1ST AVE · New York, NY 10016
1165 YORK AVENUE, GROUND FLOOR · New York, NY 10065
530 1ST AVE STE 5F · New York, NY 10016
5 E 98TH ST · New York, NY 10029
6 Peter Cooper Rd · New York, NY 10010
556 W 158th St #321931 · New York, NY 10032
530 East 74th Street · New York, NY 10021
Pins reflect street addresses where available; others are approximate (ZIP-level).
Be first to know when its status changes — join thousands already on the list.
No. Retatrutide is investigational and not FDA-approved, so it is not available by prescription in New York City or anywhere else in the U.S. The only legitimate routes today are clinical trials and Lilly's expanded access program, where your physician applies on your behalf and medical criteria must be met. RetaMaps tracks the status and the local providers most relevant to future treatment.
They are practices in medical weight management, obesity medicine, endocrinology, metabolic health, and related fields. Some currently advertise FDA-approved GLP-1 medications such as semaglutide or tirzepatide; each profile shows what the practice publicly advertises today.
Yes — 60 of the 116 tracked providers in this market indicate telehealth visits. State licensing rules determine whether a given telehealth practice can serve New York residents; confirm with the practice.
No. Inclusion on RetaMaps does not mean a provider offers or will offer retatrutide — and no legitimate provider can prescribe it today. Where a practice has told RetaMaps directly that it expects to offer retatrutide if approved, we mark that clearly on its profile.
Join the RetaMaps update list with your email and ZIP. We'll email when retatrutide's regulatory or commercial status changes relevant to your area. It's informational — not a treatment queue.